UNLABELLED: (11)C-LY2795050 is a new antagonist PET radioligand for the κ opioid receptor (KOR). In this study, we assessed the reproducibility of the binding parameters of (11)C-LY2795050 in healthy human subjects. METHODS: Sixteen healthy subjects (11 men and 5 women) underwent 2 separate 90-min PET scans with arterial input function and plasma free fraction (fP) measurements. The 2-tissue-compartment model and multilinear analysis-1 were applied to calculate 5 outcome measures in 14 brain regions: distribution volume (VT), VT normalized by fP (VT/fP), and 3 binding potentials (nondisplaceable binding potential, binding potential relative to total plasma concentration, and binding potential relative to free plasma concentration: BPND, BPP, BPF, respectively). Since KOR is distributed ubiquitously throughout the brain, there are no suitable reference regions. We used a fixed fraction of individual cerebellar VT value (VT,CER) as the nondisplaceable VT (VND) (VND = VT,CER/1.17). The relative and absolute test-retest variability and intraclass correlation coefficient were evaluated for the outcome measures of (11)C-LY2795050. RESULTS: The test-retest variability of (11)C-LY2795050 for VT was no more than 10% in any region and was 12% in the amygdala. For binding potential (BPND and BPP), the test-retest variability was good in regions of moderate and high KOR density (BPND > 0.4) and poor in regions of low density. Correction by fP (VT/fP or BPF) did not improve the test-retest performance. CONCLUSION: Our results suggest that quantification of (11)C-LY2795050 imaging is reproducible and reliable in regions with moderate and high KOR density. Therefore, we conclude that this first antagonist radiotracer is highly useful for PET studies of KOR.
UNLABELLED: (11)C-LY2795050 is a new antagonist PET radioligand for the κ opioid receptor (KOR). In this study, we assessed the reproducibility of the binding parameters of (11)C-LY2795050 in healthy human subjects. METHODS: Sixteen healthy subjects (11 men and 5 women) underwent 2 separate 90-min PET scans with arterial input function and plasma free fraction (fP) measurements. The 2-tissue-compartment model and multilinear analysis-1 were applied to calculate 5 outcome measures in 14 brain regions: distribution volume (VT), VT normalized by fP (VT/fP), and 3 binding potentials (nondisplaceable binding potential, binding potential relative to total plasma concentration, and binding potential relative to free plasma concentration: BPND, BPP, BPF, respectively). Since KOR is distributed ubiquitously throughout the brain, there are no suitable reference regions. We used a fixed fraction of individual cerebellar VT value (VT,CER) as the nondisplaceable VT (VND) (VND = VT,CER/1.17). The relative and absolute test-retest variability and intraclass correlation coefficient were evaluated for the outcome measures of (11)C-LY2795050. RESULTS: The test-retest variability of (11)C-LY2795050 for VT was no more than 10% in any region and was 12% in the amygdala. For binding potential (BPND and BPP), the test-retest variability was good in regions of moderate and high KOR density (BPND > 0.4) and poor in regions of low density. Correction by fP (VT/fP or BPF) did not improve the test-retest performance. CONCLUSION: Our results suggest that quantification of (11)C-LY2795050 imaging is reproducible and reliable in regions with moderate and high KOR density. Therefore, we conclude that this first antagonist radiotracer is highly useful for PET studies of KOR.
Authors: N Tzourio-Mazoyer; B Landeau; D Papathanassiou; F Crivello; O Etard; N Delcroix; B Mazoyer; M Joliot Journal: Neuroimage Date: 2002-01 Impact factor: 6.556
Authors: Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson Journal: J Cereb Blood Flow Metab Date: 2007-05-09 Impact factor: 6.200
Authors: Nicholas Seneca; Sjoerd J Finnema; Lars Farde; Balázs Gulyás; Håkan V Wikström; Christer Halldin; Robert B Innis Journal: Synapse Date: 2006-04 Impact factor: 2.562
Authors: N C de Lanerolle; A Williamson; C Meredith; J H Kim; H Tabuteau; D D Spencer; M L Brines Journal: Epilepsy Res Date: 1997-10 Impact factor: 3.045
Authors: Peter S Talbot; Raj Narendran; Eduardo R Butelman; Yiyun Huang; Kim Ngo; Mark Slifstein; Diana Martinez; Marc Laruelle; Dah-Ren Hwang Journal: J Nucl Med Date: 2005-03 Impact factor: 10.057
Authors: Eduardo R Butelman; Bryan D McElroy; Thomas E Prisinzano; Mary Jeanne Kreek Journal: J Pharmacol Exp Ther Date: 2019-04-11 Impact factor: 4.030
Authors: Francesca Zanderigo; Alexandra E D'Agostino; Nandita Joshi; Martin Schain; Dileep Kumar; Ramin V Parsey; Christine DeLorenzo; J John Mann Journal: Mol Imaging Biol Date: 2018-08 Impact factor: 3.488
Authors: Francesca Zanderigo; Yeona Kang; Dileep Kumar; Anastasia Nikolopoulou; P David Mozley; Paresh J Kothari; Bin He; David Schlyer; Stanley I Rapoport; Maria A Oquendo; Shankar Vallabhajosula; J John Mann; M Elizabeth Sublette Journal: Synapse Date: 2017-11-27 Impact factor: 2.562
Authors: Benjamin H Rotstein; Steven H Liang; Michael S Placzek; Jacob M Hooker; Antony D Gee; Frédéric Dollé; Alan A Wilson; Neil Vasdev Journal: Chem Soc Rev Date: 2016-08-22 Impact factor: 54.564
Authors: Mika Naganawa; Gemma L Dickinson; Ming-Qiang Zheng; Shannan Henry; Francois Vandenhende; Jennifer Witcher; Robert Bell; Nabeel Nabulsi; Shu-Fei Lin; Jim Ropchan; Alexander Neumeister; Mohini Ranganathan; Johannes Tauscher; Yiyun Huang; Richard E Carson Journal: J Pharmacol Exp Ther Date: 2015-12-01 Impact factor: 4.030
Authors: Michael S Placzek; Genevieve C Van de Bittner; Hsiao-Ying Wey; Scott E Lukas; Jacob M Hooker Journal: Neuropsychopharmacology Date: 2015-06-10 Impact factor: 7.853
Authors: Songye Li; Zhengxin Cai; Ming-Qiang Zheng; Daniel Holden; Mika Naganawa; Shu-Fei Lin; Jim Ropchan; David Labaree; Michael Kapinos; Teresa Lara-Jaime; Antonio Navarro; Yiyun Huang Journal: J Nucl Med Date: 2017-07-26 Impact factor: 10.057
Authors: Mika Naganawa; Nabeel Nabulsi; Shannan Henry; David Matuskey; Shu-Fei Lin; Lawrence Slieker; Adam J Schwarz; Nancy Kant; Cynthia Jesudason; Kevin Ruley; Antonio Navarro; Hong Gao; Jim Ropchan; David Labaree; Richard E Carson; Yiyun Huang Journal: J Nucl Med Date: 2020-08-28 Impact factor: 10.057